Oncology Collaboration and Licensing Deals 2019-2023

$3,995.00

Oncology Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2019 to 2023

Publication date
October 2023
Number of pages
1600+
Product type
Research report
Available formats
PDF document
Report edition
4
SKU
CP2201

Oncology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the oncology deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of oncology deals from 2019 to 2023.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in oncology dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the oncology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in oncology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of oncology deals signed and announced since 2019 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of oncology deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in oncology deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Key benefits

Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2019
  • Browse oncology collaboration and licensing deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

 

Report scope

Oncology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of oncology trends and structure of deals entered into by leading biopharma companies worldwide.

Oncology Collaboration and Licensing Deals includes:

  • Trends in oncology dealmaking in the biopharma industry
  • Overview of collaboration and licensing deal structure
  • Directory of oncology deal records covering pharmaceutical and biotechnology
  • The leading oncology deals by value
  • Most active oncology licensing dealmakers

In Oncology Collaboration and Licensing Deals, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.

Oncology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2019
  • Browse oncology collaboration and licensing deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in oncology dealmaking

 

2.1. Introduction

2.2. Oncology partnering over the years     

2.3. Oncology partnering by deal type

2.4. Oncology partnering by industry sector

2.5. Oncology partnering by stage of development

2.6. Oncology partnering by technology type

2.7. Oncology partnering by therapeutic indication

 

Chapter 3 – Financial deal terms for oncology partnering

 

3.1. Introduction

3.2. Disclosed financials terms for oncology partnering

3.3. Oncology partnering headline values

3.4. Oncology deal upfront payments

3.5. Oncology deal milestone payments

3.6. Oncology royalty rates

 

Chapter 4 – Leading oncology deals and dealmakers

 

4.1. Introduction

4.2. Most active in oncology partnering

4.3. List of most active dealmakers in oncology    

4.4. Top oncology deals by value

 

Chapter 5 – Oncology contract document directory

                                            

5.1. Introduction

5.2. Oncology partnering deals where contract document available

 

Chapter 6 – Oncology dealmaking by therapeutic target

 

6.1. Introduction

6.2. Deals by oncology therapeutic target

 

Deal directory

 

Deal directory – Oncology deals by company A-Z 2019 to 2023

Deal directory – Oncology deals by technology type 2019 to 2023

 

Deal type definitions

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from CurrentPartnering

 

Table of figures

 

Figure 1: Oncology partnering since 2019

Figure 2: Oncology partnering by deal type since 2019

Figure 3: Oncology partnering by industry sector since 2019

Figure 4: Oncology partnering by stage of development since 2019

Figure 5: Oncology partnering by technology type since 2019

Figure 6: Oncology partnering by indication since 2019

Figure 7: Oncology deals with a headline value

Figure 8: Oncology deals with upfront payment values

Figure 9: Oncology deals with milestone payment

Figure 10: Oncology deals with royalty rates

Figure 11: Active oncology dealmaking activity since 2019

Figure 12: Top oncology deals by value since 2019

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

1ST Biotherapeutics, 2cureX, 2seventy bio, 3B Pharmaceuticals, 3D Medicines, 3SBio, 3T Biosciences, 4baseCare, 4bases, 4C Biomed, 4D Path, 4D Pharma, 7 Hills Pharma, 9 Meters Biopharma, 48Hour Discovery, 111, 1717 Life Science Ventures, A*STAR Agency for Science, Technology and Research, A*STAR Singapore Immunology Network, A*STAR’ Institute of Molecular and Cell Biology, A2 Biotherapeutics, Aadi Bioscience, Aarvik Therapeutics, Abbisko Therapeutics, Abbvie, Abcam, AbCellera Biologics, Abcuro, Abdul Latif Jameel Health, Abera Bioscience, Abilita Bio, Abintus Bio, Ablaze Pharmaceuticals, ABL Bio, Ab Magnitude Ventures, Abound Bio, Abpro, Abramson Cancer Center, AbSci, ABVC BioPharma, Abveris, ABX, Academic and Community Cancer Research United, Academic Breast Cancer Consortium, AC Bioscience, Accelerate Brain Cancer Cure, Accent Therapeutics, Access to Comprehensive Genomic Profiling Coalition, Accord Healthcare, Accudata Systems, Accuray, AccuStem Sciences, ACEA Therapeutics, Acepodia, Acerand Therapeutics, Acerta Pharma, Achilles Therapeutics, Acibadem University, Acrivon Therapeutics, Acrotech Biopharma, Actimed Therapeutics, Actinium Pharmaceuticals, ACT Therapeutics, Actuate Therapeutics, Acucela, Acuitas Therapeutics, Adagene, AdAlta, Adamis Pharmaceuticals, Adaptate Biotherapeutics, Adaptimmune, Adaptive Biotechnologies, AdaptVac, Adcendo, ADC Therapeutics, Addario Lung Cancer Medical Institute, AdhereTech, Adimab, Adlai Nortye, AdoRx Therapeutics, ADT Pharmaceuticals, Advaite, Advanced Nuclear Medicine Ingredients, Advanz Pharma, Advaxis, Advenchen Laboratories, Aerogen, Aethlon Medical, Aethon Therapeutics, Aetion, AffaMed Therapeutics, Affimed Therapeutics, Affini-T Therapeutics, Agena Bioscience, Agencja Badan Medycznych, Agenus Bio, AgeX Therapeutics, AgonOx, AiCure, Aidence, Aidoc, Aiforia Technologies, AIkido Pharma, AI Longevity, AimedBio, AIM ImmunoTech, Ainos, Aion Therapeutic, Aitia, AiVita Biomedical, Ajax Therapeutics, Ajinomoto, Akeso Biopharma, Akoya Biosciences, Akrevia Therapeutics, AKSO Biopharmaceutical, Albany Medical College, Albert Einstein College of Medicine, Alcedis, Alchemab, Alector, Alessa Therapeutics, Aleta Biotherapeutics, Alex’s Lemonade Stand Foundation, Alkermes, ALK Positive, All4Cure, Allarity Therapeutics, Allelica, Alliance for Cancer Gene Therapy, Alliance For Clinical Trials In Oncology, Alligator Bioscience, Allist Pharma, Allogene Overland Biopharm, Allogene Therapeutics, Alloplex Biotherapeutics, Alloy Therapeutics, Almac Diagnostics, Almac Group, Almirall, Alopexx, Alpha Biopharma, Alpha Cancer Technologies, Alphageneron Pharmaceuticals, Alphamab Biopharmaceuticals, Alphamab Oncology, Alpha Tau Medical, Alpine Immune Sciences, Altavant Sciences, Alverno Clinical Laboratories, Alvotech, ALX Oncology, Amal Therapeutics, Amasa Therapeutics, Amazon Web Services, Amber Pharmacy, Ambrx, Ambry Genetics, American Association for Cancer Research, American Cancer Society, American College of Radiology, American Health Imaging, American Lung Association, American Preclinical Services, American Sexual Health Association, American Skin Association, American Society of Clinical Oncology (ASCO), American Society of Hematology, American Type Culture Collection (ATCC), Amgen, AmMax Bio, Amoy Diagnostics, Amphista Therapeutics, Amunix, Anchiano Therapeutics, AnchorDx, Angiogenesis Foundation, Angle, AnHeart Therapeutics, Anima Biotech, Animal Life Sciences, Anivive Lifesciences, Anixa Biosciences, Anji Pharma, Anju Software, Ankarys Therapeutics, Ankyra Therapeutics, Anova Enterprises, Anpac Bio-Medical Science, ANP Technologies, Antengene, Anthony Nolan, Antikor Biopharma, Antisoma Therapeutics, Apeiron Biologics, Apexigen, Apollomics, Apollon Formularies, Apollo Therapeutics, Appia Bio, Applied BioMath, Applied Cells, Applied DNA Sciences, Applied StemCell, AppliedVR, Apricity Health, Aptamer Therapeutics, Aptevo Therapeutics, Aptorum Group, Aptose Biosciences, Aqemia, Aqilion, ARase Therapeutics, Aravive Biologics, Arbor Biotechnologies, Arcellx, ArcherDX, Arch Oncology, ARC Therapeutics, Arctoris, Arcus Biosciences, Ardena, Arecor, argenx, Ariceum Therapeutics, Arizona State University, AroCell, Aromics, ArriVent Biopharma, Arsenal Biosciences, Artelo Biosciences, Arthrosi Therapeutics, Artidis, Artios Pharma, Artiva Biotherapeutics, Artizan Biosciences, ARTMS Product, Arvinas, Ascentage Pharma, Asher Biotherapeutics, Ashion Analytics, Asieris MediTech, Asieris Pharmaceuticals, AskGene Pharma, Aslan Pharma, Assistance Publique-Hôpitaux de Paris, Astellas Pharma, Astellas Pharma US, Astex Pharmaceuticals, AstraZeneca, Astrea Bioseparations, Asylia Therapeutics, Asymchem Laboratories, Atara Biotherapeutics, Athenex, Atlante Biotech, Atlas Antibodies, Atomwise, Atonco, ATP, Atreca, Atrin Pharmaceuticals, AUM Biosciences, AUM Biotech, Aura Biosciences, Aurelius Biotherapeutics, Aurigene Discovery Technologies, AusHealth, Austin Cancer Center, Australian and New Zealand Children’s Haematology / Oncology Group, Australian Nuclear Science and Technology Organisation, Australian Research Data Commons, Autolus, Avacta, AvantGen, Avatamed, Avectas, AVEO Oncology, Avera Health, Aviceda Therapeutics, Aviko Radiopharmaceuticals, AVM Biotechnology, Avrobio, Axis Therapeutics, Azra AI, B-MoGen Biotechnologies, Bach Biosciences, Baili Biopharmaceutical, BAKX Therapeutics, BAMF Health, Banner MD Anderson Cancer Center, Barbara Ann Karmanos Cancer Institute, Barer Institute, Barrow Neurological Institute, Basilea Pharmaceutica, Baxalta, Bayer, Baylor College of Medicine, Baylor Scott and White Research Institute, BC Cancer Agency, B dot Medical, Beactica, Beam Therapeutics, Beartooth Therapeutics, Bebig, BEC, Becton Dickinson, BeiGene, Beijing Genomics Institute (BGI), Beijing InnoCare Pharma, Beijing Tide Pharmaceutical, Beijing Xisike Clinical Oncology Research Foundation, Belharra Therapeutics, Bellicum Pharmaceuticals, Bennu Pharmaceuticals, BerGenBio, Beroni Group, Best Medical International, Be The Match BioTherapies, Beth Israel Deaconess Medical Center, Bethyl Laboratories, Betta Pharmaceuticals, Beyond Cancer, Beyondspring Pharmaceuticals, BGN Technologies, Bicycle Therapeutics, Biken, BinnoPharm, Bio-Cancer Treatment International, Bio-Manguinhos/Fiocruz, Bio-Rad Laboratories, Bio-Techne, Bio-Thera Solutions, bioAffinity Technologies, Bioarchitech, BioArdis, biOasis Technologies, BioAtla, Biobot Surgical, Biocare Medical, Biocartis, Biocept, Biocodices, Biocon, BioCopy, BioCure, Biocytogen, Biodesix, BioDuro, BioEclipse Therapeutics, BioEleven, BioElpida, Biofidelity, BioFluidica, Biogenar, BioGenetics, Biognosys, BioIntelliSense, BioInvent, BioKey, BiolineRX, BioLizard, Biological Dynamics, BioMark Diagnostics, Biomarker Collaborative, BioMarker Strategies, Biomedical Catalyst Fund (UK), Biomedical Primate Research Centre, BioMed Valley Discoveries, BioMed X Innovation Center, Biomica, Biomm, Biomunex Pharmaceuticals, Bionaut Labs, Bioncotech Therapeutics, Biond Biologics, BiOneCure Therapeutics, Bionetix, Bioniz Therapeutics, Bionomics, BioNova Pharmaceuticals, BioNTech, Biortus Biosciences, Biosceptre International, Biose Industrie, BioSense Global, BioSight, Biosion, Biositu Pharmaceutical Technology, BioSkryb, Biosplice, BioStrand, BioTheryX, Biotheus, BioVaxys, Bioventure MDC, BioVolume, BioXcel, Bird Foundation, Birdie Biopharmaceuticals, BitBiome, Bixink Therapeutics, BJ Bioscience, Black Diamond Therapeutics, Blackford, Blacksmith Medicines, Blackstone, Blanver, Blau Pharma, Bliss Biopharmaceutical, Bloom Science, Blu Biotech, Bluebird Bio, Bluebridge Technologies, Blue Buffalo Company, Blue Earth Diagnostics, Blue Note Therapeutics, Blueprint Medicines, Boehringer Ingelheim, Bold Therapeutics, Bolt Biotherapeutics, Bon Secours Health System, Boostimmune, Boryung Pharmaceutical, Boston Biomedical, BostonGene, Boston Immune Technologies and Therapeutics, Boston Pharmaceuticals, Boston University, Bot Image, BPGbio, Bpifrance, Bracco Imaging, BRAIN Biotech, Brainomix, Brazlex Medical Genetics, Breath Diagnostics, Brenus Pharma, BriaCell Therapeutics, BridgeBio Pharma, Bridge Medicines, BridGene Biosciences, Brigham and Women's Hospital, BrightPath Biotherapeutics, Bright Peak Therapeutics, Bristol-Myers Squibb, Broad Institute, Brooklyn ImmunoTherapeutics, Brown University, Bruker, BryoLogyx, Bugworks, Burning Rock, Busan Paik Hospital, BWXT Medical, BYOMass, Byondis, C-Bridge Capital, C-RAD, C2i Genomics, C4 Therapeutics, Calico, Calidi Biotherapeutics, Califia Pharma, California Institute for Regenerative Medicine, Calithera Biosciences, Calviri, Calyx, Cambridge Cancer Genomics, Cambridge Quantum Computing, Canadian Cancer Society, Canadian Institutes of Health Research, Canadian Nuclear Laboratories, Canaf Therapeutics, Cancer and Blood Specialty Clinic, Cancer Australia, CancerCare, Cancer Focus Fund, Cancer Hospital Chinese Academy of Medical Sciences, Cancer Prevention and Research Institute of Texas, Cancer Research Horizons, Cancer Research UK, Cancer Science Institute of Singapore, CancerVax, CanCure, Candel Therapeutics, Cannabics Pharmaceuticals, Cannomed Medical Cannabis Industries, CanProbe, Cantargia, Cantex Pharmaceuticals, Capsulomics, Caravan Biologix, Cardiff Oncology, Cardiff University, CARE, Care Access Research, Caribou Biosciences, Carina Biotech, Caris Life Sciences, Carisma Therapeutics, Carna BioSciences, Carrick Therapeutics, CARsgen, Cartexell, CarThera, Cartherics, CARTI Cancer Center, Case Western Reserve University, CASI Pharmaceuticals, Castle Biosciences, Catalent, Catamaran Bio, Catholic University Leuven, CDISC, Ceapro, Cedars-Sinai Medical Center, Cedilla Therapeutics, CeGaT, Celanese, Celcuity, Celgene, Cell&Soft, Cell-Easy, Cellares, Cellaria Biosciences, CellBion, Cellect Biotechnology, Cellectis, Cellenkos, Cellerant Therapeutics, Cellesce, Cellevolve Bio, CELLINK, Cellkey, CellMax Life, Cell Medica, Cell Mogrify, CellOrigin Biotech, Cellpath, Cell Point, Cell Therapy Manufacturing Center, Celltrion, Cellular Biomedicine, Cellworks, Celsius Therapeutics, Celularity, Cend Therapeutics, Centene, Center for Biomarker Research in Medicine, Centre for Commercialization of Cancer Immunotherapy and Regenerative Medicine, Centre for Commercialization of Regenerative Medicine (CCRM), Centre for Imaging Technology Commercialization, Centre for Probe Development and Commercialization, Centre Hospitalier Universitaire Vaudois (CHUV), Centre Leon Berard, Century Therapeutics, Cepheid, Cerecor, Cerner, CERo Therapeutics, Certara, Certis Oncology Solutions, Cevec Pharmaceuticals, CGA 369, CG Oncology, Champalimaud Foundation, Champions Oncology, CHAMPS Oncology, Changchun High & New Technology Industries, Chao Center, Charite Universitatsmedizin Berlin, Charles River Laboratories, Checkmate Pharmaceuticals, Checkpoint Therapeutics, Chemveda Life Sciences, Chengdu Gaotong Isotope, Chi-Med, Children's Hospital at Montefiore, Children's Hospital Boston, Children's Hospital Los Angeles, Children's Hospital of Philadelphia, Children's National Hospital, Children´s Oncology Group (COG), Children’s Center for Cancer and Blood Diseases (CCCBD), Children’s Hospital & Research Center Oakland, Chime Biologics, Chimeric Therapeutics, Chimerix, China Grand Pharma, China Grand Pharmaceutical, China Resources Sanjiu Medical and Pharmaceutical, Chinese University of Hong Kong, Chinook Therapeutics, Chipscreen NewWay Biosciences, Cholangiocarcinoma Foundation, Chong Kun Dang, Chongqing Jingdong Pharmaceutical, Chonnam National University, CHO Plus, ChromaCode, Chronix Biomedical, Chugai Pharmaceutical, Chung-Ang University, Cidara Therapeutics, Ciitizen, Cimeio Therapeutics, Cincinnati Children’s Hospital Medical Center, Cipla, Circuit Clinical, Citius Pharmaceuticals, City of Hope, City of Hope Comprehensive Cancer Center, CIVCO Radiotherapy, Civetta Therapeutics, Cizzle Biotech, CK Life Sciences, Clarity Pharmaceuticals, Clarus Therapeutics, Clavius Pharmaceuticals, Clearside Biomedical, Cleave Therapeutics, Cleveland Clinic, Cleveland University Hospitals, Clinical Laserthermia Systems (CLS), Clinical Research Data Sharing Alliance, Clinica Universidad Navarra, Clinigen, Clintrex Research, Clover Biopharmaceuticals, Clovis Oncology, CMAB Biopharma, Cmed, CMG Pharmaceutical, CMS Medical, CNAO Foundation, CNS Pharmaceuticals, Code Ocean, Codiak BioSciences, Coeptis Pharmaceuticals, Coeptis Therapeutics, Cofactor Genomics, Cogia Biotech, Cognizant, Coherus Biosciences, CoImmune, Colorado Melanoma Foundation, Columbia University, Columbia University Medical Center, CombiGene, Combined Therapeutics, Community Clinical Oncology Research Network, Compass Therapeutics, Complete Genomics, Complix, Compugen, ConcertAI, Concord Medical Services Holdings, Concr, Congenica, Context Therapeutics, Convergent Bioscience, Convergent Therapeutics, Corbus Pharmaceuticals, CoreBiome, Core Biotherapeutics, CorePath Laboratories, Cornell University, Corporation for Biological Research, Cortex Design, Cosylab, COTA, Covant Therapeutics, Coya Therapeutics, Creative Biolabs, Crescendo Biologics, Crescendo Bioscience, Crinetics, CRISPR Therapeutics, Criterium, Cromos Pharma, Crosscope, Crown Bioscience, CRT Pioneer Fund, CryoPort, CSPC Megalith Biopharmaceutical, CSPC Pharmaceutical Group, CStone Pharmaceuticals, CTTQ-Akeso Biomed, Cue Biopharma, Cullgen, Cullinan MICA, Cullinan Oncology, Culmination Bio, Cumberland Pharmaceuticals, Cumulus Oncology, Curadev Pharma, Curadigm, Curasight, Curative Biotechnology, Curebase, CureMatch, CureMD, CureMetrix, CURE Pharmaceutical, CureScience, Cures Within Reach, CureVac, Curis, Curium, Curon Biopharmaceutical, Curta, Curtana Pharmaceuticals, CvergenX, Cybrexa Therapeutics, Cyclenium Pharma, Cyclica, CYduct Diagnostics, Cypre, Cytea Bio, Cytecare Cancer Hospitals, Cytocom, Cytodyn, Cytogen, CytoImmune Therapeutics, CytoLynx Therapeutics, CytoMed Therapeutics, CytomX Therapeutics, CytoReason, CytoSen Therapeutics, Cytovation, CYTOVIA Therapeutics, DAAN Bio Therapeutics, Daewoong Pharmaceutical, Daiichi Sankyo, Dana-Farber Cancer Institute, Dana Farber Partners Cancer Care, Danish Cancer Society Research Center, Dante Labs, Danuo Science Group, Dartmouth College, DarwinHealth, Datavant, Day One Biopharmaceuticals, DCPrime, Debiopharm, Dechra Pharmaceuticals, Deciphera Pharmaceuticals, Decipher Biosciences, deCODE Genetics, Deep Bio, Deepcell, Deep Lens, Deerfield Management, Defence Therapeutics, DeGregorio Family Foundation, Delfi Diagnostics, Delphi Diagnostics, DeMelle OncoPharma, Dendreon, Denovium, Denovo Biopharma, Densitas, Department of Defense, DeuteRx, Deverra Therapeutics, Dewpoint Therapeutics, Diaccurate, Dialectic Therapeutics, DIAN Diagnostics, Diannei Biotechnology, Diaprost, Diatech Pharmacogenetics, DisperSol Technologies, Diverse Biotech, DKSH, DNX Biopharmaceuticals, Domainex, DoMore Diagnostics, Dong-A Pharmaceutical, DotBio, Dr. Reddy's Laboratories, Dragonfly Therapeutics, Dren Bio, Drexel University, DualityBio, Dualogics, DuChemBio, Duke University, Duke University Health System, DuPont, Dxcover, Dynavax Technologies, DYNEX Technologies, Dyve Biosciences, Eberhard Karls University Tubingen, EchelonDx, Eckert & Ziegler, Eczacibasi Pharmaceuticals, EdiGene, Edison Oncology, Editas Medicine, EditForce, Edith Wolfson Medical Center, EDP Biotech, eFFECTOR Therapeutics, Egle Therapeutics, EicOsis, Eikon Therapeutics, EirGenix, Eisai, Eisana, Elekta, Element Biosciences, Elevar Therapeutics, ElevateBio, Elevation Oncology, ELIAS Animal Health, Elicio Therapeutics, Eli Lilly, Elligo Health Research, Ellipses Pharma, Elpiscience, Elthera, Embleema, Emercell, Emerge Health, Emergence Therapeutics, Emit Imaging, EMMAC Life Sciences, Emmaus Life Sciences, Emory University, Empyrean Medical Systems, Emtora Biosciences, Enamine, Enara Bio, Endeavor BioMedicines, Endevica Bio, Endo International, Endoluxe, Energenx Medical, EnGeneIC, Enlivex, Enosi Therapeutics, Enterome Bioscience, Enterprise Ireland, Enveric Biosciences, Envisagenics, Enzolytics, Enzyvant Science, EOC Pharma, Epic, EpicentRx, Epic Sciences, EpimAb Biotherapeutics, Epiphany Dermatology, EpiVax Therapeutics, Epizyme, Epsilogen, EQRx, Erasca, Erasmus University Medical Center, Ervaxx, Esophageal Cancer Awareness Association, Esperovax, ESSA Pharma, Essen University Hospital, Essex Bio-Technology, Eterna Therapeutics, eTheRNA immunotherapies, Ethicann Pharmaceuticals, Eucure Biopharma, Eureka Eurostars, Eureka Therapeutics, Eurofins Discovery, European Commission, European Innovation Council, European Institute of Oncology (EIO), European Laboratory for Particle Physics, European Organization for Research and Treatment of Cancer, European Union, European Union Regional Development Fund, Eutilogics, Evaxion Biotech, Evercyte, Everest Medicines, Evergreen Theragnostics, Eversana, EVerZom, Evive Biotechnology, Evolent Health, Evopoint Biosciences, Evotec, EVQLV, Exacis Biotherapeutics, Exact Sciences, Exai Bio, Excellmab, ExCellThera, Excelra, Exelixis, EXINI Diagnostics, ExonanoRNA, Exopharm, Exosome Sciences, Experimental Drug Development Centre, ExpreS2ion Biotechnologies, ExScientia, Exuma Biotech, Eyam Vaccines and Immunotherapeutics, F-Star Therapeutics, Facit, Factor Bioscience, Factorial Diagnostics, Falco, Family Reach, Fapon Biopharma, Faraday Pharmaceuticals, Farcast Biosciences, Fate Therapeutics, FatiAbGen, Federation Bio, Femtogenix, FerGene, Ferring Pharmaceuticals, Ferronova, Ferrum Health, Fibrogen, Fight Colorectal Cancer, FineImmune Biotechnology, FivepHusion, Five Prime Therapeutics, Flagship Biosciences, Flame Biosciences, Flamingo Therapeutics, Flanders Innovation & Entrepreneurship, Flare Therapeutics, Flatiron Health, Florida Atlantic University Research, Flow Pharma, FLX Bio, Focal Healthcare, Foghorn Therapeutics, Follicular Lymphoma Foundation, Food and Drug Administration (FDA), ForDoz Pharma, Foresee Pharmaceuticals, Foresite Capital, FORMA Therapeutics, Fortis Therapeutics, Forty Seven, FortySix Venture Capital, Fosun Kite Biotechnology, Fosun Pharmaceutical, Foundation Medicine, Fox Chase Cancer Center, Frame Cancer Therapeutics, Francis Crick Institute, Fred Hutchinson Cancer Research Center, Freenome, Friends of Cancer Research, Fujifilm, Fujifilm medical systems, Fujitsu Laboratories, Fulgent Genetics, Fulgent Pharma, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Fusion Pharmaceuticals, Future Fields, FutureGen Biopharm, Fuzionaire Diagnostics, G1 Therapeutics, G42 Healthcare, Gabriella Miller Kids First Data Resource Center, Gadeta, Gaeta Therapeutics, Gain Therapeutics, Galecto, Galvanize Therapeutics, Gamida Cell, Gateway for Cancer Research, GC, GC Cell, GE Healthcare, Geisel School of Medicine at Dartmouth, Geisinger Health System, Gemelli Teaching Hospital, GEMoaB, GEn1E Lifesciences, GeneCentric Therapeutics, GeneCraft, GeneData, Genelux, Genentech, Geneos Therapeutics, GeneQuantum Healthcare, Generate Biomedicines, Generex Biotechnology, Geneseeq, GenesisCare, Genesis Research and Development, Genetic Immunity, Genetic Leap, Genetic Technologies, Genetron Health, GenFleet Therapeutics, Genialis, Genisphere, Genmab, Genocea Biosciences, Genome and Company, Genome Canada, Genome Insight, Genome Institute of Singapore, Genomic Testing Cooperative, Genomill Health, Genomoncology, Genor Biopharma, Genoscience, Genosco, Genprex, GenScience Pharmaceuticals, GenScript Biotech, GenScript ProBio, Genuv, George Clinical, George Mason University, Georgetown University, George Washington University, German Cancer Research Center, German Federal Ministry of Education and Research, Gestalt Diagnostics, Ghent University, Gibson Oncology, Gicell, GigaMune, GI Innovation, Gilead Sciences, Ginkgo BioWorks, GlamorousAI, Global Cancer Technology, Global Coalition for Adaptive Research, Global Liver Institute, Global Lung Cancer Coalition, GlycoMantra, GlycoMimetics, Glycostem Therapeutics, Glycotope Biotechnology, Glytherix, Gnosis Bioresearch, GNS Healthcare, GO2 Foundation for Lung Cancer, GOG Foundation, Google, Gossamer Bio, GO Therapeutics, Government of Hong Kong, Government of Ireland, Government of Netherlands, GPCR Therapeutics, Gracell Biotechnologies, Grail, Graviton Bioscience, Greenlight Biosciences, Greenwich LifeSciences, Grey Wolf Therapeutics, Gritstone Bio, Groupe d'OncologieRadiothérapie Tête Et Cou, Groupe Francophone des Myélodysplasies, GSK, GT Apeiron Therapeutics, GT Biopharma, GT Medical Technologies, Guangdong Provincial People's Hospital, Guangzhou Fanen Biotechnology, Guangzhou Ruianbo Pharmaceutical Technology, Guangzhou Ruiao Biopharmaceutical Technology, Guangzhou Xiangxue Pharmaceutical, Guardant Health, Guohong Guokang (Beijing) Health Technology Development, Gyros Protein Technologies, H3 Biomedicine, Hackensack Meridian Health, Hadassah Medical Center, HaemaLogiX, Hairy Cell Leukemia Foundation, Halberd, HalioDx, HALO Diagnostics, Halo Dx, HanAll Pharmaceuticals, HanchorBio, Hande Sciences, Handok Pharmaceuticals, Hangzhou CNK Therapeutics, Hangzhou Zhongmei Huadong Pharmaceutical, Hanmi Pharmaceutical, HanX Biopharmaceuticals, Harbinger Health, Harbour Biomed, Harpoon Therapeutics, Harvard Medical School, Harvard T.H. Chan School of Public Health, Harvard University, HavaH Therapeutics, HAYA Therapeutics, HCW Biologics, HealthCare Konnect, HealthMyne, Healx, HebeCell, Hebrew University of Jerusalem, Heidelberg Pharma, Heligenics, Helio Health, Helmholtz Zentrum Munchen, Helomics, Helsinki University Central Hospital (HUCH) Comprehensive Cancer Center, Helsinn Healthcare, Helsinn Therapeutics, Hematology-Oncology Associates of Central New York, Hemogenyx, Henan Cancer Hospital, Hengrui Therapeutics, Henlius Biotech, Henry M. Jackson Foundation, Hera BioLabs, Heska, HiberCell, HIBio, Hibiscus BioVentures, HiFiBio, Highlight Therapeutics, Hikma Pharmaceuticals, Hillstream BioPharma, HiloProbe, HistoIndex, Hisun BioRay, HitGen, HK inno.N, HLB Therapeutics, Hoag Memorial Hospital Presbyterian, Hoffmann La Roche, Holobeam Technologies, Hologic, Hong Kong University of Science & Technology, Hookipa Pharma, Horizon Discovery, Horizon Europe, Hospital Clinic of Barcelona, Hospital for Sick Children, Hospital of University of Strasbourg, Hoth Therapeutics, HotSpot Therapeutics, Houston Pharmaceuticals, HTG Molecular Diagnostics, Huadong Medicine, Hualan Genetic, Hubrecht Organoid Technology, Huma, Humanigen, Humanitas University, Hummingbird Bioscience, Huntsman Cancer Institute, Huons, Hutchmed, Huyabio International, HUYA Bioscience, Hyundai Hope On Wheels, I-mab, IASO Biotherapeutics, Iaso Pharmaceuticals, Iaso Therapeutics, IBA, Ibex Medical Analytics, iBio, IBM, iCAD, Icahn School of Medicine at Mount Sinai, ICAN, IcanoMAB, Ichnos Sciences, Ichor Medical Systems, Icon, Iconic Therapeutics, Idaho Urologic Institute, IDEAYA Biosciences, IDEOlogy Health, Idera Pharmaceuticals, IGEA Clinical Biophysics, IGM Biosciences, Ikanik Farms, Ikena Oncology, Ikonisys, Ikonopedia, Iksuda Therapeutics, Ildong Pharmaceutical, Ilera Therapeutics, Illumina, Image Analysis, ImaginAb, IMBdx, ImCheck Therapeutics, Immagene, Immatics Biotechnologies, Immedica, Immix Biopharma, Immodulon Therapeutics, Immorna, Immunaccel, Immunai, Immune-Onc Therapeutics, ImmuneOncia Therapeutics, Immune Therapeutics, ImmuNext, ImmunGene, Immunicom, Immunitas Therapeutics, ImmunityBio, ImmunoChina Pharmaceuticals, Immunocore, ImmunoForge, ImmunoGen, Immunogenesis, Immunome, Immunomedics, Immunomic Therapeutics, ImmunoPhotonics, ImmunoPrecise Antibodies, ImmunoScape, ImmunOs Therapeutics, Immunovia, Immunscape, ImmuPharma, Immutep, ImmVira, IMPACT Therapeutics, Imperial College London, Impetis Biosciences, Imugene, IMV, Imvaq Therapeutics, In4Derm, IncellDx, Inceptor Bio, Inceptua, Incyte, Indapta Therapeutics, Indiana University, Indica Labs, Indivumed, Industrial Centre for Artificial Intelligence Research in Digital Diagnostics, Infinity Pharmaceuticals, Inflammatory Breast Cancer Research Foundation, InflaRx, Inflection Biosciences, Inform Diagnostics, Inhibikase Therapeutics, Inhibrx, Inivata, INmune Bio, InnDura Therapeutics, InnoBation, Innoplexus, Innosuisse, Innovate BC, Innovate UK, Innovation Norway, Innovative Medicines Initiative (IMI), Innovent Biologics, Inovio Pharmaceuticals, InProTher, Inserm, InSightec, Insilico Biotechnology, Insilico Medicine, InSitu Biologics, InSphero, Inspirna, Institut Bergonie, Institut Carnot CALYM, Institut Curie, Institute for Molecular Medicine Finland, Institute for Myeloma and Bone Cancer Research, Institute for Research in Immunology and Cancer – Commercialization of Research, Institute of Cancer Research, Institut Gustave Roussy, Institut Paoli-Calmettes, Institut Pasteur, Intas Pharmaceuticals, Integra Connect, Integral Molecular, Integrated Biosciences, Integra Therapeutics, Intellia Therapeutics, Intelligent Medical Objects, Intellikine, Intensity Therapeutics, Intermountain Healthcare, Intermountain Precision Genomics, International Association for the Study of Lung Cancer, International Centers for Precision Oncology Foundation, Intima Bioscience, Intonation Research Laboratories, IntraOp Medical, Invasight, Invectys, Invenio Imaging, Invenra, Inventum Genetics, inviCRO, Invitae, InVivoScribe, InxMed, IO Biotech, iOncologi, iOnctura, Ionis Pharmaceuticals, Ionova, IONTAS, Iovance Biotherapeutics, IOVaxis Therapeutics, iPrime Therapeutics, iProgen Biotech, Ipsen, IQVIA, IRBM, Isofol Medical, Isologic Innovative Radiopharmaceuticals, Isotopia Molecular Imaging, Israeli National Authority for Technological Innovation, Italian Association for the Study of Pancreas, iTeos Therapeutics, Iterion Therapeutics, ITM Isotopen Technologien, IUCT, Ivy Brain Tumor Center, Ixaka, Ix Therapeutics, Jackson Laboratory, Jacobio Pharmaceuticals, JAMP Pharma Group, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Janux Therapeutics, Japan Agency for Medical Research and Development, Jazz Pharmaceuticals, Jefferson Healthcare, Jemincare, Jenthera Therapeutics, Jerome Canady Research Institute for Advanced Biological and Technological Sciences, Jiangsu Alphamab, Jiangsu Chia Tai Tianqing Pharmaceutical, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Medicine, Jiangsu Hengrui Pharmaceuticals, Jiangsu Wuzhong Pharmaceutical, J Ints Bio, JMT-Bio, Jnana Therapeutics, John Hopkins University School of Medicines, Johns Hopkins Kimmel Cancer Center, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, John Wayne Cancer Institute, Josep Carreras Leukaemia Research Institute, Jounce Therapeutics, JSC Pharmadis, JSR, JSR Life Sciences, Jubilant Therapeutics, Juniper Biologics, Juno Therapeutics, Junshi Biosciences, Juntendo University, Juventas Therapeutics, Juvise Pharmaceuticals, JW Biotechnology, JW Therapeutics, Kahn-Sagol-Maccabi, KAHR Medical, Kainos Medicines, Kalbe Genexine Biologics, KaliVir Immunotherapeutics, Kalos Therapeutics, Kamada, Kanazawa University, Kanyr Pharma, Karkinos Healthcare, Karolinska Institute, Karolinska University Hospital, Kartos Therapeutics, Karyopharm Therapeutics, Kazia Therapeutics, KDAc Therapeutics, KDx Diagnostics, Keio Gijuku University, Kelun-Biotech Biopharmaceutical, Kephera Diagnostics, Keymed Biosciences, Kheiron Medical Technologies, Kiadis Pharma, Kibur Medical, Kineta, Kings College London, Kiniksa Pharmaceuticals, Kinnate Biopharma, Kintor, Kiq, Kirin Brewery, Kiromic Biopharma, Kissei Pharmaceutical, Kite Pharma, Kiyatec, Klaria, Kleo Pharmaceuticals, Knight Therapeutics, Kobe University, Korea Drug Development Fund, Korea Pharma, Kovina Therapeutics, Krankenhaus Nordwest, Kriya Therapeutics, Kronos Bio, KSQ Therapeutics, Kumquat Biosciences, Kura Oncology, KYAN Therapeutics, Kyn Therapeutics, Kyowa Hakko Kirin, LabConnect, LabGenius, Laboratory Corporation of America, Laboratory of Pathology, Laekna, Laevoroc Oncology, La Jolla Institute for Allergy & Immunology, LamKap Bio Group, LaNova Medicines, Lantern Pharma, Lantheus Holding, Lantheus Medical Imaging, Lassen Therapeutics, Latvian Institute of Organic Synthesis, Lava Therapeutics, Lawson Health Research Institute, Leal Health, Leap Therapeutics, Lee Health, Lee Moffitt Cancer Center, Legend Biotech, LegoChem Biosciences, Lehigh Valley Health Network, Leica Biosystems, Leidos, Leo Cancer Care, Lepu Biopharma, Les Laboratoires Servier, Leucid Bio, Leukemia & Lymphoma Society, LeukoCom, Lexent Bio, Lexicon Pharmaceuticals, LG Chem, LG Life Sciences, LianBio, Liaoning-Dalian Lvshun District Government, Libera Bio, LifeMax Laboratories, LifeOmic, Life Raft Group, LifeSensors, Lifespin, LIfT BioSciences, Ligand Pharmaceuticals, Lightpoint Medical, Li Ka Shing Foundation, Limbus AI, LimmaTech Biologics, Lineage Cell Therapeutics, LineaRx, LinKinVax, Linnaeus Therapeutics, Lion TCR, LIPAC Oncology, Lisata Therapeutics, LiteCure Medical, LiteVax, Little Warrior Foundation, Livzon Mabpharm, Lixte Biotechnology, Lodo Therapeutics, Logomix, Longwood University, Lonza, Lotus Pharmaceuticals, Loxo Oncology, Lubrizol, Lucence, Ludwig Institute for Cancer Research, LumaBridge, Luminary Therapeutics, Luminex, Lumos Pharma, Lunaphore, Lundquist Institute, Lung Biotechnology, Lung Cancer Foundation of America, Lung Cancer Initiative, Lung Cancer Research Foundation, LUNGevity Foundation, Lunit, Lupagen, Lupin, Lupin Limited, Lurie Children's Hospital of Chicago, Luxembourg Institute of Health, Lyell Immunopharma, Lynk Pharmaceuticals, Lytix Biopharma, Lyvgen Biopharma, M2Gen, MaaT Pharma, MAB Discovery, Mablink Bioscience, mAbsolve, Mabwell Bioscience, Macao Kiang Wu Hospital, Maccabi Healthcare Services, Machavert Pharmaceuticals, Macomics, Macrogen, Macrogenics, MagBio Genomics, MagCorp, Magenta Therapeutics, Magle Chemoswed, Magnetic Insight, MAIA Biotechnology, Maine Medical Center, Mainz Biomed, Mammoth Biosciences, Manhattan BioSolutions, MapKure, Marasco Laboratory, Marengo Therapeutics, Maria Curie-Sklodowska University, Marker Therapeutics, Mark Foundation for Cancer Research, Maruho, Mary Crowley Cancer Research Center, Massachusetts General Hospital, Massachusetts Institute of Technology, Massachusetts Life Sciences Center, Mass General Brigham, Massive Bio, Mateon Therapeutics, Mater Research, Matrix Biomed, Mauna Kea Technologies, Maverick Therapeutics, MaveriX Oncology, Mawi DNA Technologies, Maxcyte, MaxiVAX, Mayo Clinic, McGill University, McKesson, McMaster University, MD Anderson Cancer Center, MDimune, MDS, Medac, Medexus Pharmaceuticals, Medial EarlySign, MEDIAN Technologies, Medical College of Wisconsin, Medical Research Council, Medical University of Graz, Medical University of Vienna, Medical University South Carolina, Medicenna Therapeutics, Medicines Patent Pool Foundation, MEDiC Life Sciences, Medidata Solutions, MediGene, MedImmune, Medipath, MediSix Therapeutics, Medison Pharma, Medivir, Medivizor, Medolife Rx, MedPacto, MEDSIR, Medtech4Health, Medtronic, Meiji Seika, MEI Pharma, Melanoma Research Alliance, Melax Technologies, Memorial Sloan Kettering Cancer Center, Memo Therapeutics, Menarini, Mendus, Mentice, MercachemSyncom, Merck and Co, Merck KGaA, Merck Sharpe & Dohme, Mereo BioPharma, Mersana Therapeutics, Merus, Mestag Therapeutics, Metabolon, Metafora Biosystems, Metagenomi, MetaSight Diagnostics, Methodist Hospital Houston, Metis Therapeutics, MetOx Technologies, MGFB, Michelson Center, Michigan State University, Microba Life Sciences, Microbiotica, Micronoma, Microsoft, Microviable Therapeutics, Milburn Foundation, Millennium, MilliporeSigma, Mimetas, MimiVax, MIM Software, Minaris Regenerative Medicine, MindPeak, MindRank AI, Minerva Biotechnologies, Minerva Imaging, Minotaur Therapeutics, Mirada Medical, Mirati Therapeutics, miR Scientific, MiRXES, Mission Bio, Mitacs, MITRE, MITRO Biotech, Mitsubishi Tanabe Pharma, MJH Life Sciences, Moderna, Molcure, Molecular Health, Molecular Targeting Technologies, Molecular Templates, Moleculin Biotech, Monopar Therapeutics, Montefiore Health System, Morphogenesis, MorphoSys, Mor Research Applications, Morris Animal Foundation, Mosaic ImmunoEngineering, Motiv, Mount Sinai Health System, MPM Capital, mProbe Laboratories, MRM Proteomics, MSD, MThera Pharma, Multidisciplinary Association for Psychedelics Studies, Multimmune, Multiple Myeloma Research Foundation, Multitude Therapeutics, Mundipharma, Munich Technical University, Mustang Bio, MyBiotics Pharma, Myeloid Therapeutics, Mylan Laboratories, Mymetics, myNEO, Myovant Sciences, My Personal Therapeutics, Myriad Genetics, Mythic Therapeutics

 

For a full list of companies please email us at enquiry@currentpartnering.com

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.